Orange Book product · Generic (ANDA)
BEXAROTENE
BEXAROTENE
At a glance
Jul 25, 2018
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 25, 2018
8 yr ago
Today
Pharmaceutical detail
Active ingredient
BEXAROTENE
Strength
75MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 209886
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of BEXAROTENE
- 2000TARGRETINBrand (NDA)
NDA 021056 · BAUSCH
- 1999TARGRETINBrand (NDA)
NDA 021055 · BAUSCH
- 2024BEXAROTENEGeneric (ANDA)
ANDA 210352 · CIPLA
- 2024BEXAROTENEGeneric (ANDA)
ANDA 208628 · ASCENT PHARMS INC
- 2022BEXAROTENEGeneric (ANDA)
ANDA 215398 · AMNEAL
- 2021BEXAROTENEGeneric (ANDA)
ANDA 209931 · TEVA PHARMS USA
- 2020BEXAROTENEGeneric (ANDA)
ANDA 203663 · HIKMA
- 2018BEXAROTENEGeneric (ANDA)
ANDA 210105 · AMNEAL PHARMS NY
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209861 · ANI PHARMS
- 2014BEXAROTENEGeneric (ANDA)
ANDA 203174 · BIONPHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
